TD Cowen Maintains Buy on Milestone Pharmaceuticals, Lowers Price Target to $5
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
TD Cowen analyst Ritu Baral maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $8 to $5.
TD Cowen analyst Ritu Baral maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $8 to $5.
